ERBB2 and breast carcinoma: The Heart Failure Association-International Cardio-Oncology Society (HFA-ICOS) tool was the most frequently validated (11 times), mainly in patients with breast cancer receiving HER2 (human epidermal growth factor receptor 2) targeted therapies (5/11, 45%).